{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:30:21Z","timestamp":1771479021009,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Japan Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jjcc.2019.07.007","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:04:48Z","timestamp":1565827488000},"page":"208-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study"],"prefix":"10.1016","volume":"75","author":[{"given":"Hiroshi","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiaki","family":"Umeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Komoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2019.07.007_bib0005","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0010","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1253\/circj.CJ-10-1183","article-title":"Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. The ARISTOTLE-J study","volume":"75","author":"Ogawa","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0015","series-title":"Eliquis\u00ae tablets Japanese package insert version 8","year":"2017"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0020","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1253\/circj.CJ-16-1337","article-title":"Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients: Fushimi AF Registry","volume":"81","author":"Yamashita","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.joa.2016.11.003","article-title":"Current use of direct oral anticoagulants for atrial fibrillation in Japan: findings from the SAKURA AF Registry","volume":"33","author":"Okumura","year":"2017","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0030","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1080\/03007995.2018.1478282","article-title":"Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data","volume":"34","author":"Kohsaka","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0035","doi-asserted-by":"crossref","first-page":"e008150","DOI":"10.1161\/JAHA.117.008150","article-title":"Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation","volume":"7","author":"Chan","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/joim.12683","article-title":"Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study","volume":"283","author":"Staerk","year":"2018","journal-title":"J Intern Med"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0045","doi-asserted-by":"crossref","first-page":"e0191722","DOI":"10.1371\/journal.pone.0191722","article-title":"Apixaban 5 and 2.5mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity-score-matched approach","volume":"13","author":"Li","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0050","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1160\/TH17-10-0733","article-title":"Effectiveness and safety of non-vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation","volume":"118","author":"Hohnloser","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/STROKEAHA.117.018395","article-title":"Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis","volume":"49","author":"Proietti","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0060","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.joa.2017.05.008","article-title":"Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients","volume":"33","author":"Umei","year":"2017","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0065","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/joa3.12184","article-title":"Safety and effectiveness of apixaban in Japanese patients with non-valvular atrial fibrillation in clinical practice: a regulatory post-marketing surveillance, the STANDARD study","volume":"35","author":"Inoue","year":"2019","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0075","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0080","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0085","doi-asserted-by":"crossref","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0090","doi-asserted-by":"crossref","first-page":"e007633","DOI":"10.1161\/JAHA.117.007633","article-title":"Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)","volume":"7","author":"Steinberg","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0095","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1161\/CIRCULATIONAHA.115.015710","article-title":"Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study","volume":"132","author":"Maura","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jjcc.2018.12.013","article-title":"Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-Dabigatran Surveillance","volume":"73","author":"Inoue","year":"2019","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijcard.2018.01.141","article-title":"The EXPAND study: efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation","volume":"258","author":"Shimokawa","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamacardio.2016.1829","article-title":"Apixaban 5mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial","volume":"1","author":"Alexander","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0115","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1253\/circj.CJ-18-0535","article-title":"Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation: findings from the SAKURA AF Registry","volume":"82","author":"Okumura","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jjcc.2019.01.001","article-title":"Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese patients with atrial fibrillation","volume":"74","author":"Ikeda","year":"2019","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0125","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1253\/circj.CJ-14-1245","article-title":"Low body weight is associated with the incidence of stroke in atrial fibrillation patients \u2013 insight from the Fushimi AF Registry","volume":"79","author":"Hamatani","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.amjcard.2016.04.036","article-title":"Impact of body mass index on the prognosis of Japanese patients with non-valvular atrial fibrillation","volume":"118","author":"Inoue","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0135","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/europace\/eut333","article-title":"Atrial fibrillation patients do not benefit from acetylsalicyclic acid","volume":"16","author":"Sjalander","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0140","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1253\/circj.CJ-18-0872","article-title":"Current status, time trends and outcomes of combination therapy with oral anticoagulant and antiplatelet drug in patients with atrial fibrillation: the Fushimi AF registry","volume":"82","author":"Masunaga","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.07.007_bib0145","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2017.10.085","article-title":"Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation","volume":"71","author":"Chao","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508719302230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508719302230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:01:57Z","timestamp":1760274117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508719302230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0914508719302230"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.07.007","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}